Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025

Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals

Alembic Pharmaceuticals commissions new facility at Pithampur

Briefs: Alembic Pharmaceuticals and Shelter Pharma

Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience

Alembic Pharmaceuticals receives USFDA final approval for Divalproex Sodium Delayed-Release Capsules

Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA

Briefs: Alembic Pharmaceuticals and Veerhealth Care

The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market

Alembic Pharmaceuticals gets USFDA tentative approval for OTC

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr

US Generics grew 5% to Rs. 467 Crores for the quarter

Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals

Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic